APO RESEARCH · REPORT
Oncology Drugs
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
Product & engineering
Understand the product.
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
Selected research
Industry Growth & Trends
Global Oncology Drugs Industry Growth and Trends Forecast to 2032
Market perspective
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Read the full market overview
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
According to APO Research, the global Oncology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
This report provides a structured, data-driven view of the global Oncology Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Oncology Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oncology Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oncology Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Oncology Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Oncology Drugs Market by Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Oncology Drugs Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Oncology Drugs Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Others
Oncology Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oncology Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
Applications
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory or Lung Cancer
- Others
Companies covered
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Oncology Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Oncology Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Oncology Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Oncology Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Oncology Drugs Market Size (2021-2032)
- 1.5.1 North America Oncology Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Oncology Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Oncology Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Oncology Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Oncology Drugs Market Size Growth Rate (2021-2032)
2 Oncology Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Chemotherapy
- 2.1.2 Targeted Therapy
- 2.1.3 Immunotherapy (Biologic Therapy)
- 2.1.4 Hormonal Therapy
- 2.1.5 Others
- 2.2 Global Oncology Drugs Market Size by Type
- 2.2.1 Global Oncology Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Oncology Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Oncology Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Oncology Drugs Market Size by Regions
- 2.3.1 North America Oncology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Oncology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Oncology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Oncology Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Oncology Drugs Market Size Breakdown by Type (2021-2026)
3 Oncology Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Blood Cancer
- 3.1.2 Breast Cancer
- 3.1.3 Gastrointestinal Cancer
- 3.1.4 Prostate Cancer
- 3.1.5 Respiratory or Lung Cancer
- 3.1.6 Others
- 3.2 Global Oncology Drugs Market Size by Application
- 3.2.1 Global Oncology Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Oncology Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Oncology Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Oncology Drugs Market Size by Regions
- 3.3.1 North America Oncology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Oncology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Oncology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Oncology Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Oncology Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Oncology Drugs Industry Trends
- 4.2 Oncology Drugs Industry Drivers
- 4.3 Oncology Drugs Industry Opportunities and Challenges
- 4.4 Oncology Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Oncology Drugs Revenue (2021-2026)
- 5.2 Global Oncology Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Oncology Drugs Key Company Headquarters & Area Served
- 5.4 Global Oncology Drugs Company, Product Type & Application
- 5.5 Global Oncology Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Oncology Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Oncology Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Oncology Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Roche
- 6.1.1 Roche Company Information
- 6.1.2 Roche Business Overview
- 6.1.3 Roche Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Roche Oncology Drugs Product Portfolio
- 6.1.5 Roche Recent Developments
- 6.2 Celgene
- 6.2.1 Celgene Company Information
- 6.2.2 Celgene Business Overview
- 6.2.3 Celgene Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Celgene Oncology Drugs Product Portfolio
- 6.2.5 Celgene Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis Oncology Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Oncology Drugs Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Johnson & Johnson
- 6.5.1 Johnson & Johnson Company Information
- 6.5.2 Johnson & Johnson Business Overview
- 6.5.3 Johnson & Johnson Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Johnson & Johnson Oncology Drugs Product Portfolio
- 6.5.5 Johnson & Johnson Recent Developments
- 6.6 Merck & Co.
- 6.6.1 Merck & Co. Company Information
- 6.6.2 Merck & Co. Business Overview
- 6.6.3 Merck & Co. Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Merck & Co. Oncology Drugs Product Portfolio
- 6.6.5 Merck & Co. Recent Developments
- 6.7 AstraZeneca
- 6.7.1 AstraZeneca Company Information
- 6.7.2 AstraZeneca Business Overview
- 6.7.3 AstraZeneca Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AstraZeneca Oncology Drugs Product Portfolio
- 6.7.5 AstraZeneca Recent Developments
- 6.8 Pfizer
- 6.8.1 Pfizer Company Information
- 6.8.2 Pfizer Business Overview
- 6.8.3 Pfizer Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Pfizer Oncology Drugs Product Portfolio
- 6.8.5 Pfizer Recent Developments
- 6.9 Amgen
- 6.9.1 Amgen Company Information
- 6.9.2 Amgen Business Overview
- 6.9.3 Amgen Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Amgen Oncology Drugs Product Portfolio
- 6.9.5 Amgen Recent Developments
- 6.10 Eli Lilly
- 6.10.1 Eli Lilly Company Information
- 6.10.2 Eli Lilly Business Overview
- 6.10.3 Eli Lilly Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Eli Lilly Oncology Drugs Product Portfolio
- 6.10.5 Eli Lilly Recent Developments
- 6.11 AbbVie
- 6.11.1 AbbVie Company Information
- 6.11.2 AbbVie Business Overview
- 6.11.3 AbbVie Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 AbbVie Oncology Drugs Product Portfolio
- 6.11.5 AbbVie Recent Developments
- 6.12 Takeda
- 6.12.1 Takeda Company Information
- 6.12.2 Takeda Business Overview
- 6.12.3 Takeda Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Takeda Oncology Drugs Product Portfolio
- 6.12.5 Takeda Recent Developments
- 6.13 Astellas
- 6.13.1 Astellas Company Information
- 6.13.2 Astellas Business Overview
- 6.13.3 Astellas Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Astellas Oncology Drugs Product Portfolio
- 6.13.5 Astellas Recent Developments
- 6.14 Ipsen
- 6.14.1 Ipsen Company Information
- 6.14.2 Ipsen Business Overview
- 6.14.3 Ipsen Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Ipsen Oncology Drugs Product Portfolio
- 6.14.5 Ipsen Recent Developments
- 6.15 Sanofi
- 6.15.1 Sanofi Company Information
- 6.15.2 Sanofi Business Overview
- 6.15.3 Sanofi Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Sanofi Oncology Drugs Product Portfolio
- 6.15.5 Sanofi Recent Developments
- 6.16 Bayer
- 6.16.1 Bayer Company Information
- 6.16.2 Bayer Business Overview
- 6.16.3 Bayer Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Bayer Oncology Drugs Product Portfolio
- 6.16.5 Bayer Recent Developments
- 6.17 Biogen Idec
- 6.17.1 Biogen Idec Company Information
- 6.17.2 Biogen Idec Business Overview
- 6.17.3 Biogen Idec Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Biogen Idec Oncology Drugs Product Portfolio
- 6.17.5 Biogen Idec Recent Developments
- 6.18 Teva
- 6.18.1 Teva Company Information
- 6.18.2 Teva Business Overview
- 6.18.3 Teva Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Teva Oncology Drugs Product Portfolio
- 6.18.5 Teva Recent Developments
- 6.19 Otsuka
- 6.19.1 Otsuka Company Information
- 6.19.2 Otsuka Business Overview
- 6.19.3 Otsuka Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 Otsuka Oncology Drugs Product Portfolio
- 6.19.5 Otsuka Recent Developments
- 6.20 Eisai
- 6.20.1 Eisai Company Information
- 6.20.2 Eisai Business Overview
- 6.20.3 Eisai Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.20.4 Eisai Oncology Drugs Product Portfolio
- 6.20.5 Eisai Recent Developments
- 6.21 Merck KGaA
- 6.21.1 Merck KGaA Company Information
- 6.21.2 Merck KGaA Business Overview
- 6.21.3 Merck KGaA Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.21.4 Merck KGaA Oncology Drugs Product Portfolio
- 6.21.5 Merck KGaA Recent Developments
- 6.22 Gilead Sciences
- 6.22.1 Gilead Sciences Company Information
- 6.22.2 Gilead Sciences Business Overview
- 6.22.3 Gilead Sciences Oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.22.4 Gilead Sciences Oncology Drugs Product Portfolio
- 6.22.5 Gilead Sciences Recent Developments
7 North America
- 7.1 North America Oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Oncology Drugs Market Size by Country (2021-2026)
- 7.3 North America Oncology Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Oncology Drugs Market Size by Country (2021-2026)
- 8.3 Europe Oncology Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Oncology Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Oncology Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Oncology Drugs Market Size by Country (2021-2026)
- 10.3 South America Oncology Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Oncology Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Oncology Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst